Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Systematic review of botulinum toxin treatment for oromandibular dystonia.

Comella CL.

Toxicon. 2018 Jun 1;147:96-99. doi: 10.1016/j.toxicon.2018.02.006. Epub 2018 Feb 14. Review.

PMID:
29453996
2.

Effect of High-Intensity Treadmill Exercise on Motor Symptoms in Patients With De Novo Parkinson Disease: A Phase 2 Randomized Clinical Trial.

Schenkman M, Moore CG, Kohrt WM, Hall DA, Delitto A, Comella CL, Josbeno DA, Christiansen CL, Berman BD, Kluger BM, Melanson EL, Jain S, Robichaud JA, Poon C, Corcos DM.

JAMA Neurol. 2018 Feb 1;75(2):219-226. doi: 10.1001/jamaneurol.2017.3517.

3.

The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study.

Factor SA, Remington G, Comella CL, Correll CU, Burke J, Jimenez R, Liang GS, O'Brien CF.

J Clin Psychiatry. 2017 Nov/Dec;78(9):1344-1350. doi: 10.4088/JCP.17m11777.

4.

Longitudinal studies of botulinum toxin in cervical dystonia: Why do patients discontinue therapy?

Jinnah HA, Comella CL, Perlmutter J, Lungu C, Hallett M; Dystonia Coalition Investigators.

Toxicon. 2018 Jun 1;147:89-95. doi: 10.1016/j.toxicon.2017.09.004. Epub 2017 Sep 6. Review.

PMID:
28888929
5.

Dystonia: Then and now.

Comella CL.

Parkinsonism Relat Disord. 2018 Jan;46 Suppl 1:S66-S69. doi: 10.1016/j.parkreldis.2017.06.025. Epub 2017 Jun 30. Review.

PMID:
28843401
6.

Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry.

Trosch RM, Espay AJ, Truong D, Gil R, Singer C, LeWitt PA, Lew MF, Tagliati M, Adler CH, Chen JJ, Marchese D, Comella CL.

J Neurol Sci. 2017 May 15;376:84-90. doi: 10.1016/j.jns.2017.02.042. Epub 2017 Feb 21.

7.

Effects of 2 Years of Exercise on Gait Impairment in People With Parkinson Disease: The PRET-PD Randomized Trial.

Rafferty MR, Prodoehl J, Robichaud JA, David FJ, Poon C, Goelz LC, Vaillancourt DE, Kohrt WM, Comella CL, Corcos DM.

J Neurol Phys Ther. 2017 Jan;41(1):21-30.

8.

Poster 296 AbobotulinumtoxinA Injection Patterns in Patients with Cervical Dystonia from the ANCHOR-CD Registry Study.

Comella CL, Camba GC, Truong D, Espay AJ, Snyder D, Marchese D, Trosch R.

PM R. 2016 Sep;8(9S):S256-S257. doi: 10.1016/j.pmrj.2016.07.468. Epub 2016 Sep 24. No abstract available.

PMID:
27673052
9.

Progressive resistance exercise restores some properties of the triphasic EMG pattern and improves bradykinesia: the PRET-PD randomized clinical trial.

David FJ, Robichaud JA, Vaillancourt DE, Poon C, Kohrt WM, Comella CL, Corcos DM.

J Neurophysiol. 2016 Nov 1;116(5):2298-2311. doi: 10.1152/jn.01067.2015. Epub 2016 Aug 31.

10.

The best medicine? The influence of physical activity and inactivity on Parkinson's disease.

LaHue SC, Comella CL, Tanner CM.

Mov Disord. 2016 Oct;31(10):1444-1454. doi: 10.1002/mds.26728. Review.

PMID:
27477046
11.

Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology.

Simpson DM, Hallett M, Ashman EJ, Comella CL, Green MW, Gronseth GS, Armstrong MJ, Gloss D, Potrebic S, Jankovic J, Karp BP, Naumann M, So YT, Yablon SA.

Neurology. 2016 May 10;86(19):1818-26. doi: 10.1212/WNL.0000000000002560. Epub 2016 Apr 18.

12.

Clinical and genetic features of cervical dystonia in a large multicenter cohort.

LeDoux MS, Vemula SR, Xiao J, Thompson MM, Perlmutter JS, Wright LJ, Jinnah HA, Rosen AR, Hedera P, Comella CL, Weissbach A, Junker J, Jankovic J, Barbano RL, Reich SG, Rodriguez RL, Berman BD, Chouinard S, Severt L, Agarwal P, Stover NP.

Neurol Genet. 2016 Apr 11;2(3):e69. doi: 10.1212/NXG.0000000000000069. eCollection 2016 Jun.

13.

Development of the Comprehensive Cervical Dystonia Rating Scale: Methodology.

Comella CL, Fox SH, Bhatia KP, Perlmutter JS, Jinnah HA, Zurowski M, McDonald WM, Marsh L, Rosen AR, Waliczek T, Wright LJ, Galpern WR, Stebbins GT.

Mov Disord Clin Pract. 2015 Jun;2(2):135-141. Epub 2015 Apr 6.

14.

Clinimetric testing of the comprehensive cervical dystonia rating scale.

Comella CL, Perlmutter JS, Jinnah HA, Waliczek TA, Rosen AR, Galpern WR, Adler CA, Barbano RL, Factor SA, Goetz CG, Jankovic J, Reich SG, Rodriguez RL, Severt WL, Zurowski M, Fox SH, Stebbins GT.

Mov Disord. 2016 Apr;31(4):563-9. doi: 10.1002/mds.26534. Epub 2016 Mar 12.

15.

Botulinum Toxin Treatment of Cervical Dystonia.

Bledsoe IO, Comella CL.

Semin Neurol. 2016 Feb;36(1):47-53. doi: 10.1055/s-0035-1571210. Epub 2016 Feb 11. Review.

PMID:
26866496
16.

Effects of Endurance Exercise Training on The Motor and Non-Motor Features of Parkinson's Disease: A Review.

Lamotte G, Rafferty MR, Prodoehl J, Kohrt WM, Comella CL, Simuni T, Corcos DM.

J Parkinsons Dis. 2015;5(4):993. doi: 10.3233/JPD-159002. No abstract available.

PMID:
26683786
17.

Effects of Endurance Exercise Training on The Motor and Non-Motor Features of Parkinson's Disease: A Review.

Lamotte G, Rafferty MR, Prodoehl J, Kohrt WM, Comella CL, Simuni T, Corcos DM.

J Parkinsons Dis. 2015;5(3):621. doi: 10.3233/JPD-159001. No abstract available.

PMID:
26406143
18.

Exercise improves cognition in Parkinson's disease: The PRET-PD randomized, clinical trial.

David FJ, Robichaud JA, Leurgans SE, Poon C, Kohrt WM, Goldman JG, Comella CL, Vaillancourt DE, Corcos DM.

Mov Disord. 2015 Oct;30(12):1657-63. doi: 10.1002/mds.26291. Epub 2015 Jul 6.

19.

Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders.

Jost WH, Benecke R, Hauschke D, Jankovic J, Kaňovský P, Roggenkämper P, Simpson DM, Comella CL.

Drug Des Devel Ther. 2015 Apr 1;9:1913-26. doi: 10.2147/DDDT.S79193. eCollection 2015. Review.

20.

When brawn benefits brain: physical activity and Parkinson's disease risk.

Tanner CM, Comella CL.

Brain. 2015 Feb;138(Pt 2):238-9. doi: 10.1093/brain/awu351. No abstract available.

21.

Distinct functional and macrostructural brain changes in Parkinson's disease and multiple system atrophy.

Planetta PJ, Kurani AS, Shukla P, Prodoehl J, Corcos DM, Comella CL, McFarland NR, Okun MS, Vaillancourt DE.

Hum Brain Mapp. 2015 Mar;36(3):1165-79. doi: 10.1002/hbm.22694. Epub 2014 Nov 21.

22.

Effects of endurance exercise training on the motor and non-motor features of Parkinson's disease: a review.

Lamotte G, Rafferty MR, Prodoehl J, Kohrt WM, Comella CL, Simuni T, Corcos DM.

J Parkinsons Dis. 2015;5(1):21-41. doi: 10.3233/JPD-140425. Review. Erratum in: J Parkinsons Dis. 2015;5(4):993. J Parkinsons Dis. 2015;5(3):621.

PMID:
25374272
23.

IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated.

Evidente VG, Truong D, Jankovic J, Comella CL, Grafe S, Hanschmann A.

J Neurol Sci. 2014 Nov 15;346(1-2):116-20. doi: 10.1016/j.jns.2014.08.004. Epub 2014 Aug 10.

24.

State neurologic societies and the AAN: Strengthening neurology for the future.

Narayanaswami P, Showers D, Levi B, Showers M, Jones EC, Busis NA, Comella CL, Pulst SM, Hosey JP, Griggs RC.

Neurol Clin Pract. 2014 Jun;4(3):247-255.

25.

Subthalamic nucleus--sensorimotor cortex functional connectivity in de novo and moderate Parkinson's disease.

Kurani AS, Seidler RD, Burciu RG, Comella CL, Corcos DM, Okun MS, MacKinnon CD, Vaillancourt DE.

Neurobiol Aging. 2015 Jan;36(1):462-9. doi: 10.1016/j.neurobiolaging.2014.07.004. Epub 2014 Jul 11.

26.

Two-year exercise program improves physical function in Parkinson's disease: the PRET-PD randomized clinical trial.

Prodoehl J, Rafferty MR, David FJ, Poon C, Vaillancourt DE, Comella CL, Leurgans SE, Kohrt WM, Corcos DM, Robichaud JA.

Neurorehabil Neural Repair. 2015 Feb;29(2):112-22. doi: 10.1177/1545968314539732. Epub 2014 Jun 24.

27.

Beyond a motor disorder: a prospective evaluation of sleep quality in cervical dystonia.

Eichenseer SR, Stebbins GT, Comella CL.

Parkinsonism Relat Disord. 2014 Apr;20(4):405-8. doi: 10.1016/j.parkreldis.2014.01.004. Epub 2014 Jan 15.

PMID:
24486141
28.

Treatment of restless legs syndrome.

Comella CL.

Neurotherapeutics. 2014 Jan;11(1):177-87. doi: 10.1007/s13311-013-0247-9. Review.

29.

Designing clinical trials for dystonia.

Galpern WR, Coffey CS, Albanese A, Cheung K, Comella CL, Ecklund DJ, Fahn S, Jankovic J, Kieburtz K, Lang AE, McDermott MP, Shefner JM, Teller JK, Thompson JL, Yeatts SD, Jinnah HA.

Neurotherapeutics. 2014 Jan;11(1):117-27. doi: 10.1007/s13311-013-0221-6. Review.

30.

Cognitive and motor function in long-duration PARKIN-associated Parkinson disease.

Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Orbe Reilly M, Ruiz D, Louis ED, Comella CL, Nance MA, Bressman SB, Scott WK, Tanner CM, Mickel SF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak KE, Friedman JH, Pfeiffer RF, Marsh L, Hiner B, Payami H, Molho E, Factor SA, Nutt JG, Serrano C, Arroyo M, Ottman R, Pauciulo MW, Nichols WC, Clark LN, Marder KS.

JAMA Neurol. 2014 Jan;71(1):62-7. doi: 10.1001/jamaneurol.2013.4498.

31.

A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia.

Evidente VG, Fernandez HH, LeDoux MS, Brashear A, Grafe S, Hanschmann A, Comella CL.

J Neural Transm (Vienna). 2013 Dec;120(12):1699-707. doi: 10.1007/s00702-013-1048-3. Epub 2013 Jun 19.

32.

Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial.

Schapira AH, McDermott MP, Barone P, Comella CL, Albrecht S, Hsu HH, Massey DH, Mizuno Y, Poewe W, Rascol O, Marek K.

Lancet Neurol. 2013 Aug;12(8):747-55. doi: 10.1016/S1474-4422(13)70117-0. Epub 2013 May 31.

33.

Diffusion tensor imaging of Parkinson's disease, atypical parkinsonism, and essential tremor.

Prodoehl J, Li H, Planetta PJ, Goetz CG, Shannon KM, Tangonan R, Comella CL, Simuni T, Zhou XJ, Leurgans S, Corcos DM, Vaillancourt DE.

Mov Disord. 2013 Nov;28(13):1816-22. doi: 10.1002/mds.25491. Epub 2013 May 14.

34.

Efficacy and Safety of IncobotulinumtoxinA in Subjects Previously Treated with Botulinum Toxin Versus Toxin-Naïve Subjects with Cervical Dystonia.

Fernandez HH, Pappert EJ, Comella CL, Evidente VG, Truong DD, Verma A, Jankovic J.

Tremor Other Hyperkinet Mov (N Y). 2013 Apr 18;3. pii: tre-03-140-2921-1. doi: 10.7916/D87P8X43. Print 2013.

35.

A two-year randomized controlled trial of progressive resistance exercise for Parkinson's disease.

Corcos DM, Robichaud JA, David FJ, Leurgans SE, Vaillancourt DE, Poon C, Rafferty MR, Kohrt WM, Comella CL.

Mov Disord. 2013 Aug;28(9):1230-40. doi: 10.1002/mds.25380. Epub 2013 Mar 27.

36.

Force control deficits in individuals with Parkinson's disease, multiple systems atrophy, and progressive supranuclear palsy.

Neely KA, Planetta PJ, Prodoehl J, Corcos DM, Comella CL, Goetz CG, Shannon KL, Vaillancourt DE.

PLoS One. 2013;8(3):e58403. doi: 10.1371/journal.pone.0058403. Epub 2013 Mar 11.

37.

Differences in brain activation between tremor- and nontremor-dominant Parkinson disease.

Prodoehl J, Planetta PJ, Kurani AS, Comella CL, Corcos DM, Vaillancourt DE.

JAMA Neurol. 2013 Jan;70(1):100-6. doi: 10.1001/jamaneurol.2013.582.

38.

Tai chi for patients with Parkinson's disease.

Corcos DM, Comella CL, Goetz CG.

N Engl J Med. 2012 May 3;366(18):1737-8; author reply 1738. doi: 10.1056/NEJMc1202921. No abstract available.

PMID:
22551137
39.

Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia.

Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S; U.S. XEOMIN Cervical Dystonia Study Group.

J Neurol Sci. 2011 Sep 15;308(1-2):103-9. doi: 10.1016/j.jns.2011.05.041. Epub 2011 Jul 18.

PMID:
21764407
40.

Early-onset primary dystonia.

Robottom BJ, Weiner WJ, Comella CL.

Handb Clin Neurol. 2011;100:465-79. doi: 10.1016/B978-0-444-52014-2.00036-7. Review.

PMID:
21496603
41.

Jaw-opening dystonia: Quality of life after botulinum toxin injections.

Charous SJ, Comella CL, Fan W.

Ear Nose Throat J. 2011 Feb;90(2):E9.

PMID:
21328222
42.

Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study.

Caccappolo E, Alcalay RN, Mejia-Santana H, Tang MX, Rakitin B, Rosado L, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner CM, Mickel SF, Andrews HF, Waters C, Fahn S, Cote LJ, Frucht S, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer RF, Marsh L, Hiner B, Siderowf AD, Ross BM, Verbitsky M, Kisselev S, Ottman R, Clark LN, Marder KS.

J Int Neuropsychol Soc. 2011 Jan;17(1):91-100. doi: 10.1017/S1355617710001190. Epub 2010 Nov 24.

43.

Sleep disorders in Parkinson's disease.

Videnovic A, Comella CL.

Handb Clin Neurol. 2011;99:997-1010. doi: 10.1016/B978-0-444-52007-4.00019-9. No abstract available.

PMID:
21056240
44.

Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo.

Menza M, Dobkin RD, Marin H, Gara M, Bienfait K, Dicke A, Comella CL, Cantor C, Hyer L.

Mov Disord. 2010 Aug 15;25(11):1708-14. doi: 10.1002/mds.23168.

45.

Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study.

Marder KS, Tang MX, Mejia-Santana H, Rosado L, Louis ED, Comella CL, Colcher A, Siderowf AD, Jennings D, Nance MA, Bressman S, Scott WK, Tanner CM, Mickel SF, Andrews HF, Waters C, Fahn S, Ross BM, Cote LJ, Frucht S, Ford B, Alcalay RN, Rezak M, Novak K, Friedman JH, Pfeiffer RF, Marsh L, Hiner B, Neils GD, Verbitsky M, Kisselev S, Caccappolo E, Ottman R, Clark LN.

Arch Neurol. 2010 Jun;67(6):731-8. doi: 10.1001/archneurol.2010.95.

46.

Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study.

Schapira AH, Albrecht S, Barone P, Comella CL, McDermott MP, Mizuno Y, Poewe W, Rascol O, Marek K.

Mov Disord. 2010 Aug 15;25(11):1627-32. doi: 10.1002/mds.23143.

PMID:
20544810
47.

Basal ganglia hypoactivity during grip force in drug naïve Parkinson's disease.

Spraker MB, Prodoehl J, Corcos DM, Comella CL, Vaillancourt DE.

Hum Brain Mapp. 2010 Dec;31(12):1928-41. doi: 10.1002/hbm.20987. Epub 2010 Mar 11.

PMID:
20225221
48.

Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease.

Alcalay RN, Mejia-Santana H, Tang MX, Rakitin B, Rosado L, Ross B, Verbitsky M, Kisselev S, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner C, Mickel SF, Andrews HF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Ottman R, Clark LN, Marder KS, Caccappolo E.

J Clin Exp Neuropsychol. 2010 Aug;32(7):775-9. doi: 10.1080/13803390903521018. Epub 2010 Feb 24.

49.

Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease.

Alcalay RN, Mejia-Santana H, Tang MX, Rosado L, Verbitsky M, Kisselev S, Ross BM, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner C, Mickel SF, Andrews HF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Caccappolo E, Ottman R, Clark LN, Marder KS.

Arch Neurol. 2009 Dec;66(12):1517-22. doi: 10.1001/archneurol.2009.267.

50.

High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease.

Vaillancourt DE, Spraker MB, Prodoehl J, Abraham I, Corcos DM, Zhou XJ, Comella CL, Little DM.

Neurology. 2009 Apr 21;72(16):1378-84. doi: 10.1212/01.wnl.0000340982.01727.6e. Epub 2009 Jan 7. Erratum in: Neurology. 2009 Jun 9;72(23):2059.

Supplemental Content

Loading ...
Support Center